ravulizumab-cwvz 300 MG in 30 ML Injection

RxCUI
2107320
RxNorm name
ravulizumab-cwvz 300 MG in 30 ML Injection
Display name
ravulizumab-cwvz 300 MG in 30 ML Injection
Full name
ravulizumab-cwvz 300 MG in 30 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:14

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761108Ultomirisravulizumab-cwvz351(a)Rx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a9a590d9-0217-43c7-908d-e62a71279791ravulizumab-cwvz 300 MG in 30 ML Injection [PSN] · 30 ML ravulizumab-cwvz 10 MG/ML Injection [SCD] · ravulizumab-cwvz 300 MG per 30 ML Injection [SY]319These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS ® (ravulizumab-cwvz) injection, for intravenous use Initial U.S. Approval: 201820251009